Previous close | 0.6323 |
Open | 0.6112 |
Bid | 0.5901 x 800 |
Ask | 0.6000 x 4000 |
Day's range | 0.5613 - 0.6300 |
52-week range | 0.4600 - 3.8900 |
Volume | |
Avg. volume | 850,862 |
Market cap | 52.602M |
Beta (5Y monthly) | 2.18 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.5190 |
Earnings date | 25 July 2022 - 29 July 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 6.07 |
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
CAMBRIDGE, Mass., May 17, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the upcoming H.C. Wainwright Global Investment Conference May 23-25, 2022.
Infinity (INFI) delivered earnings and revenue surprises of 0% and 65.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?